<p>LIR Life Sciences Corp. (CSE: <strong>SKNY</strong>)(OTC PINK: <strong>BBCMF</strong>)(Frankfurt: <strong>N790</strong>, WKN: <strong>A41QA9</strong>)（&#34;LIR&#34;或&#34;公司&#34;）很高兴地宣布其正在进行的比较小鼠研究的积极中期结果，该研究评估了细胞穿透肽（CPP）促进的无针注射 GLP/GIP 基础疗法的递送。在这项中期分析中，接受新型 semaglutide/CPP 局部制剂治疗的动物在口服葡萄糖负荷后血糖水平降低，与未治疗的对照组相比，表明在该模型中具有药理学上有意义的活性。</p>
<p>该研究比较了局部皮肤应用的 CPP 制剂 semaglutide（GLP-1 类药物，代表 GLP/GIP 基础疗法）与可注射 semaglutide 和未治疗对照组在葡萄糖耐受模型中的效果。这些中期数据代表了在受控的体内环境中首次展示 CPP 促进的 GLP/GIP 基础疗法的局部制剂可以接近可注射对照药物的血糖控制特征。观察到局部制剂的血糖曲线平坦化是公司平台的一个关键技术里程碑。这支持了 CPP 基础系统能够以可测量且在标准代谢模型中具有功能意义的水平穿透皮肤屏障的大型肽药物的科学论点。</p>
<p>在这项中期分析中，接受 CPP 制剂局部 semaglutide 治疗的动物在标准化的口服葡萄糖负荷后血糖水平较未治疗对照组有所降低。虽然对照动物在葡萄糖给药后血糖出现明显峰值，但注射 semaglutide 组和 CPP 促进的局部组均有效抑制了这一峰值，并更快地恢复到基线水平。重要的是，CPP 局部组的血糖水平在观察期间保持稳定。这些发现表明，CPP 促进的局部制剂可能以药理学上有意义的水平通过皮肤屏障递送活性药物，并在该模型中实现持续的血糖控制。</p>
<p>这些中期结果为 LIR 的 CPP 促进的经皮平台在 GLP/GIP 基础疗法中的应用提供了初步的体内支持。此外，这一局部 CPP semaglutide 的展示是完善制剂、确认剂量范围和指导未来研究的重要一步。这些发现还支持继续资助一项现有的比较研究，该研究利用不同的 GLP/GIP 基础疗法，预计结果将很快公布。</p>
<p>&#34; <em>即使在这个中期阶段，我们对研究所显示的结果感到鼓舞。我们的 CPP 促进的局部制剂在标准模型中产生了有意义的降糖效果。这是一个重要的步骤，因为它支持追求无针注射方法的论点，并为我们下一阶段的工作提供了明确的基础，包括完善制剂、缩小剂量范围以及完成已经进行的额外比较研究，</em>&#34; LIR Life Sciences 首席执行官 Edward Mills 表示。</p>
<p><strong>关于 LIR Life Sciences Corp.</strong></p>
<p>LIR Life Sciences 专注于研究和开发可扩展且经济实惠的肥胖治疗方法，采用新型药物递送方式。该公司正在推进一种经皮贴片和其他模仿 GLP-1 的创新递送系统，GLP-1 是一种自然产生的激素，有助于调节食欲和血糖。这些疗法可能为注射药物提供替代方案。目标是在发达市场和新兴市场中改善获取、依从性和成本效率。LIR Life Sciences 旨在通过基于已建立化合物和经过验证的科学的实用解决方案来应对全球肥胖负担。</p>
<p><strong>代表 LIR Life Sciences Corp.</strong></p>
<p>&#34; <strong>Edward Mills 博士，</strong>&#34;</p>
<p>首席执行官</p>
<p>如需更多信息，请联系：</p>
<p>Edward Mills 博士</p>
<p>首席执行官</p>
<p>电话：+1 888 436 7772</p>
<p>电子邮件：investors@lirlife.com</p>
<p><em>CSE 及其监管服务提供商对本新闻稿的充分性或准确性不承担任何责任。没有任何证券交易所、证券委员会或其他监管机构批准或不批准此处包含的信息。</em></p>
<p><strong>关于前瞻性信息的警示说明</strong></p>
<p>本新闻稿包含的声明和信息，在不构成历史事实的情况下，可能构成适用证券法意义上的 “前瞻性信息”，该信息基于公司管理层的当前预期、估计、预测、展望、信念和假设。前瞻性信息通常通过诸如 “相信”、“项目”、“目标”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将”、“会” 等类似表达来识别。在本新闻稿中，前瞻性信息包括与临时专利申请的提交、公司的研发活动、公司的财务和商业前景、其资产及其他事项相关的声明。特别是，前瞻性信息包括关于公司透皮给药平台、该平台与 GLP/GIP 基础药物的潜在兼容性、预临床研究的预期结果以及未来无针代谢疗法的潜在开发的声明。尽管公司相信这些前瞻性信息所基于的预期和假设是合理的，但不应对前瞻性信息过度依赖，因为公司无法保证其将被证明是正确的。由于前瞻性信息涉及未来事件和条件，因此其本质上涉及固有的风险和不确定性。许多因素可能导致实际未来事件与本新闻稿中的前瞻性信息存在重大差异。本新闻稿中包含的前瞻性信息明确受到本警示声明的限制。本新闻稿中包含的前瞻性信息截至本日期作出，公司不承担任何义务公开更新或修订任何前瞻性信息，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
<p><strong>来源：</strong> Lir Life Sciences Corp.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTcyNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTcyNA"/></p>

ATNF

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

<p>LIR Life Sciences Corp. 宣布了一项关于 CPP 促进的无针注射 GLP/GIP 基础疗法的比较小鼠研究的积极中期结果。研究显示，与未处理的对照组相比，接受新型 semaglutide/CPP 外用制剂治疗的动物血糖水平降低。这表明 CPP 促进的外用制剂能够有效地通过皮肤屏障输送活性药物，实现持续的血糖控制。这些发现支持进一步开发用于肥胖治疗的经皮给药平台，旨在提供可替代注射药物的选择</p>

<p>LIR Life Sciences Corp. (CSE: <strong>SKNY</strong>)(OTC PINK: <strong>BBCMF</strong>)(Frankfurt: <strong>N790</strong>, WKN: <strong>A41QA9</strong>) (&#34;LIR&#34; or the &#34;Company&#34;) is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this interim analysis, animals treated with a novel semaglutide/CPP topical formulation demonstrated reduced blood glucose following an oral glucose challenge compared with untreated controls, indicating pharmacologically meaningful activity in this model.</p>
<div class="lb-trans"><p>LIR Life Sciences Corp. (CSE: <strong>SKNY</strong>)(OTC PINK: <strong>BBCMF</strong>)(Frankfurt: <strong>N790</strong>, WKN: <strong>A41QA9</strong>)（&#34;LIR&#34;或&#34;公司&#34;）很高兴地宣布其正在进行的比较小鼠研究的积极中期结果，该研究评估了细胞穿透肽（CPP）促进的无针注射 GLP/GIP 基础疗法的递送。在这项中期分析中，接受新型 semaglutide/CPP 局部制剂治疗的动物在口服葡萄糖负荷后血糖水平降低，与未治疗的对照组相比，表明在该模型中具有药理学上有意义的活性。</p>
</div><p>The study compares a topical, skin-applied CPP formulation of semaglutide, a GLP-1 analogue representative of GLP/GIP-based therapies, against injectable semaglutide and untreated controls in a glucose tolerance model. These interim data represent one of the first demonstrations, in a controlled in vivo setting, that a CPP-enabled topical formulation of a GLP/GIP-based therapy can approach the glucose control profile of an injectable comparator. Observing a flattened glucose curve from a skin-applied formulation is a key technical milestone for the Company's platform. It supports the underlying scientific thesis that CPP-based systems may be able to move large peptide drugs across the skin barrier at levels that are not only measurable, but functionally meaningful in a standard metabolic model.</p>
<div class="lb-trans"><p>该研究比较了局部皮肤应用的 CPP 制剂 semaglutide（GLP-1 类药物，代表 GLP/GIP 基础疗法）与可注射 semaglutide 和未治疗对照组在葡萄糖耐受模型中的效果。这些中期数据代表了在受控的体内环境中首次展示 CPP 促进的 GLP/GIP 基础疗法的局部制剂可以接近可注射对照药物的血糖控制特征。观察到局部制剂的血糖曲线平坦化是公司平台的一个关键技术里程碑。这支持了 CPP 基础系统能够以可测量且在标准代谢模型中具有功能意义的水平穿透皮肤屏障的大型肽药物的科学论点。</p>
</div><p>In this interim analysis, animals that received the CPP-formulated topical semaglutide showed a reduction in blood glucose compared with untreated controls following a standardized oral glucose challenge. While control animals exhibited a pronounced spike in blood sugar after glucose administration, both the injected semaglutide group and the CPP-enabled topical group demonstrated effective blunting of this spike and a faster return toward baseline. Importantly, blood glucose levels in the CPP topical group remained stable over the observation period. These findings indicate that the CPP-enabled topical formulation is likely delivering active drug across the skin barrier at pharmacologically meaningful levels and is achieving sustained glucose control in this model.</p>
<div class="lb-trans"><p>在这项中期分析中，接受 CPP 制剂局部 semaglutide 治疗的动物在标准化的口服葡萄糖负荷后血糖水平较未治疗对照组有所降低。虽然对照动物在葡萄糖给药后血糖出现明显峰值，但注射 semaglutide 组和 CPP 促进的局部组均有效抑制了这一峰值，并更快地恢复到基线水平。重要的是，CPP 局部组的血糖水平在观察期间保持稳定。这些发现表明，CPP 促进的局部制剂可能以药理学上有意义的水平通过皮肤屏障递送活性药物，并在该模型中实现持续的血糖控制。</p>
</div><p>These interim results provide preliminary in vivo support for LIR's CPP-enabled transdermal platform for GLP/GIP-based therapies. Further, this demonstration with topical CPP semaglutide is an important step toward refining formulations, confirming dose ranges and guiding the path to future studies. These findings also support the continued funding of an existing comparative study utilizing a different GLP/GIP-based therapy, for which results are anticipated shortly.</p>
<div class="lb-trans"><p>这些中期结果为 LIR 的 CPP 促进的经皮平台在 GLP/GIP 基础疗法中的应用提供了初步的体内支持。此外，这一局部 CPP semaglutide 的展示是完善制剂、确认剂量范围和指导未来研究的重要一步。这些发现还支持继续资助一项现有的比较研究，该研究利用不同的 GLP/GIP 基础疗法，预计结果将很快公布。</p>
</div><p>&#34; <em>Even at this interim stage, we are encouraged by what the study is showing. Our CPP-enabled topical formulation is producing a meaningful glucose-lowering effect in a standard model. This is an important step because it supports the thesis of pursuing a needle-free approach and gives us a clear basis for the next phase of work, including refining the formulation, narrowing the dose range, and completing the additional comparative studies already underway,</em>&#34; said Edward Mills, CEO of LIR Life Sciences.</p>
<div class="lb-trans"><p>&#34; <em>即使在这个中期阶段，我们对研究所显示的结果感到鼓舞。我们的 CPP 促进的局部制剂在标准模型中产生了有意义的降糖效果。这是一个重要的步骤，因为它支持追求无针注射方法的论点，并为我们下一阶段的工作提供了明确的基础，包括完善制剂、缩小剂量范围以及完成已经进行的额外比较研究，</em>&#34; LIR Life Sciences 首席执行官 Edward Mills 表示。</p>
</div><p><strong>About LIR Life Sciences Corp.</strong></p>
<div class="lb-trans"><p><strong>关于 LIR Life Sciences Corp.</strong></p>
</div><p>LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.</p>
<div class="lb-trans"><p>LIR Life Sciences 专注于研究和开发可扩展且经济实惠的肥胖治疗方法，采用新型药物递送方式。该公司正在推进一种经皮贴片和其他模仿 GLP-1 的创新递送系统，GLP-1 是一种自然产生的激素，有助于调节食欲和血糖。这些疗法可能为注射药物提供替代方案。目标是在发达市场和新兴市场中改善获取、依从性和成本效率。LIR Life Sciences 旨在通过基于已建立化合物和经过验证的科学的实用解决方案来应对全球肥胖负担。</p>
</div><p><strong>ON BEHALF OF LIR LIFE SCIENCES CORP.,</strong></p>
<div class="lb-trans"><p><strong>代表 LIR Life Sciences Corp.</strong></p>
</div><p>&#34; <strong>Dr. Edward Mills,</strong>&#34;</p>
<div class="lb-trans"><p>&#34; <strong>Edward Mills 博士，</strong>&#34;</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>For more information, please contact:</p>
<div class="lb-trans"><p>如需更多信息，请联系：</p>
</div><p>Dr. Edward Mills</p>
<div class="lb-trans"><p>Edward Mills 博士</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>Tel: +1 888 436 7772</p>
<div class="lb-trans"><p>电话：+1 888 436 7772</p>
</div><p>Email: investors@lirlife.com</p>
<div class="lb-trans"><p>电子邮件：investors@lirlife.com</p>
</div><p><em>Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.</em></p>
<div class="lb-trans"><p><em>CSE 及其监管服务提供商对本新闻稿的充分性或准确性不承担任何责任。没有任何证券交易所、证券委员会或其他监管机构批准或不批准此处包含的信息。</em></p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息的警示说明</strong></p>
</div><p>This news release contains statements and information that, to the extent that they are not historical fact, may constitute &#34;forward-looking information&#34; within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as &#34;believe&#34;, &#34;project&#34;, &#34;aim&#34;, &#34;expect&#34;, &#34;anticipate&#34;, &#34;estimate&#34;, &#34;intend&#34;, &#34;strategy&#34;, &#34;future&#34;, &#34;opportunity&#34;, &#34;plan&#34;, &#34;may&#34;, &#34;should&#34;, &#34;will&#34;, &#34;would&#34;, and similar expressions and, in this news release, includes statements relating to the filing of the provisional patent application, the research and development activities of the Company, the financial and business prospects of the Company, its assets and other matters. In particular, forward-looking information includes statements regarding the Company's transdermal delivery platform, the potential compatibility of the platform with GLP/GIP-based medicines, the anticipated outcomes of preclinical studies, and the potential development of future needle-free metabolic therapies. Although the Company believes that the expectations and assumptions on which such forward- looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.</p>
<div class="lb-trans"><p>本新闻稿包含的声明和信息，在不构成历史事实的情况下，可能构成适用证券法意义上的 “前瞻性信息”，该信息基于公司管理层的当前预期、估计、预测、展望、信念和假设。前瞻性信息通常通过诸如 “相信”、“项目”、“目标”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将”、“会” 等类似表达来识别。在本新闻稿中，前瞻性信息包括与临时专利申请的提交、公司的研发活动、公司的财务和商业前景、其资产及其他事项相关的声明。特别是，前瞻性信息包括关于公司透皮给药平台、该平台与 GLP/GIP 基础药物的潜在兼容性、预临床研究的预期结果以及未来无针代谢疗法的潜在开发的声明。尽管公司相信这些前瞻性信息所基于的预期和假设是合理的，但不应对前瞻性信息过度依赖，因为公司无法保证其将被证明是正确的。由于前瞻性信息涉及未来事件和条件，因此其本质上涉及固有的风险和不确定性。许多因素可能导致实际未来事件与本新闻稿中的前瞻性信息存在重大差异。本新闻稿中包含的前瞻性信息明确受到本警示声明的限制。本新闻稿中包含的前瞻性信息截至本日期作出，公司不承担任何义务公开更新或修订任何前瞻性信息，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
</div><p><strong>SOURCE:</strong> Lir Life Sciences Corp.</p>
<div class="lb-trans"><p><strong>来源：</strong> Lir Life Sciences Corp.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTcyNA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1131724"/></p>

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies | BBCMF Stock News

StockTitan

180 Life Sciences

LIR 生命科学公司公布了关于新型 CPP 支持的 GLP/GIP 基础疗法透皮递送的比较动物研究的积极中期临床前结果 | BBCMF 股票新闻